Nanobiotix radiographic data shows high response rates in lung cancer trial
Nanobiotix (NASDAQ:NBTX) announced promising preliminary efficacy and safety data from Part 1 of the ongoing CONVERGE study at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting.










